Loading
Flumatinib is Hansoh Pharma's second-generation BCR-ABL inhibitor, approved in China in 2019 for newly diagnosed chronic-phase chronic myeloid leukaemia.
Flumatinib is an imatinib derivative developed by Hansoh Pharma. The NMPA approved it in November 2019 for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase, after the FESTnd phase 3 trial reported deeper and faster molecular responses than imatinib. It is the first BCR-ABL inhibitor discovered and developed in China.
Blocks the BCR-ABL fusion kinase that drives chronic myeloid leukaemia, with higher potency than imatinib. Connects to BCR::ABL1 (Philadelphia chromosome).
1.Flumatinib slips into a pocket on BCR::ABL1 (Philadelphia chromosome).
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2019 | Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia, chronic phase |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Flumatinib" OR ABSTRACT:"Flumatinib" OR TITLE:"HH-GV-678" OR ABSTRACT:"HH-GV-678" OR TITLE:"Xinfu" OR ABSTRACT:"Xinfu") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Flumatinib, not a curated reading list.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.